Evidence suggests that psoriasis together with other cardiovascular (CV) risk factors is associated with increased vascular morbidity, but it is not clear whether psoriasis is an independent risk factor. Consecutive patients (n ¼ 33; 35.6 + 5.7 years; 13 females) with mild psoriasis (Psoriasis Area and Severity Index <10) without comorbidities and 33 healthy participants (36.3 + 5.9 years; 15 females) were enrolled. Both groups underwent echocardiography, speckle tracking (2-dimensional strain echocardiography [2D-SE]), and pulse wave velocity (PWV) testing. Clinical and conventional echocardiographic characteristics were comparable between both groups. Global longitudinal strain (GLS) was significantly lower (P ¼ .002) in the psoriasis group (22.39% + 2.28%) than in controls (24.15% + 2.17%). The PWV was significantly lower (P ¼ .004) in controls (8.06 + 1.68 m/s) than in the psoriasis group (9.23 + 1.53 m/s). Significant correlations between GLS and disease duration (r ¼ À.66, P < .0001) and between GLS and patient age at diagnosis (r ¼ .48, P ¼ .0043) were found. Psoriasis may be an independent CV risk factor, causing cardiac and vascular impairment. Both 2D-SE and PWV may be useful tools for the screening of CV risk in these patients.
Introduction
Psoriasis is a chronic immune-mediated inflammatory disease of the skin, affecting the 1% to 3% of the population. 1, 2 Several studies highlighted an association between psoriasis and coronary artery disease (CAD). 3, 4 Evidence suggests that a combination of psoriasis with other cardiovascular (CV) risk factors leads to an increased incidence of CAD, 5, 6 but whether psoriasis is an independent risk factor for CAD has not been established.
The systemic inflammatory response in psoriasis is regulated by T helper 1 and T helper 17 lymphocytes, which play a key role in its pathogenesis, [7] [8] [9] [10] leading to endothelial damage with premature progression to atherosclerosis. 11, 12 Currently, there are few data about the development of subclinical myocardial dysfunction and vascular changes in patients with mild psoriasis. Two-dimensional strain echocardiography (2D-SE) is a valid tool to quantify both left ventricular (LV) longitudinal and circumferential deformations, allowing the detection of subclinical changes in systolic function and providing a quantitative assessment of regional LV function. [13] [14] [15] [16] [17] Arterial stiffness has been identified as an independent prognostic factor for patients with CV disease (CVD). [18] [19] [20] [21] An increased pulse wave velocity (PWV), a noninvasive index of arterial stiffness, predicts CV events in different clinical conditions. [22] [23] [24] Increased arterial stiffness negatively affects cardiac structure and function with systolic and diastolic abnormalities. 22, 25, 26 The aim of our study was to test cardiac performance and vascular stiffness in patients with mild psoriasis in the absence of other CV risk factors or drug treatment. Cardiac function was assessed by echocardiography both with conventional indexes, according to the guidelines of the American Society of Echocardiography, 27 and through new technologies (speckle tracking analysis with evaluation of longitudinal and circumferential strain [CS] ). For the evaluation of vascular stiffness, carotid-femoral PWV was measured by Doppler ultrasound.
Materials and Methods

Enrolled Population
Consecutive patients (n ¼ 33; 35.6 + 5.7 years; 13 [40%] females) with mild psoriasis were enrolled and compared with 33 healthy controls (36.3 + 5.9 years; 15 [45%] females). Only patients with mild psoriasis with no CV risk factors and no systemic drug therapy were enrolled. Disease severity was assessed by a dermatologist using the Psoriasis Area and Severity Index (PASI) score: A score <10 was used to classify psoriasis as mild. We excluded participants with (1) PASI ! 10, (2) any drug therapy, (3) smoking, (4) hypertension, (5) diabetes mellitus, (6) renal failure, (7) LV kinetic abnormalities due to left bundle branch block and/or pacemaker stimulation, (8) LV ejection fraction <50%, (9) chronic CAD, (10) arrhythmias, (11) previous cardiac surgery, (12) cardiomyopathies, (13) moderate-to-severe valve disorders, and (14) poor acoustic window. Physical examination of all patients was carried out by a qualified dermatologist. All echocardiographic scans and Doppler data of carotid-femoral PWV were acquired by an experienced cardiologist and processed "off-line" by another cardiologist blinded for participant diagnosis. Clinical characteristics are summarized in Table 1 .
Our local ethics committee approved the investigation, judging it compliant with the principles of the Helsinki Declaration. Written informed consent was obtained from all participants.
Patients were enrolled from the Department of Dermatology where they attended for periodic follow-up. We evaluated 232 patients affected by psoriasis attending the Department of Dermatology during 15 months; 162 (70%) patients were affected by psoriasis in a degree from moderate to severe and were already on drug therapy: Among them, 68% were also affected by other CV risk factors and 9% had a previous episode of CAD. Thirty-seven (16%) patients had mild psoriasis but were already receiving pharmacological therapy because of concomitant CV risk factors (7 were hypertensive; 10 hypertensive and smokers; 8 hypertensive and dyslipidemic; 6 diabetic; 3 diabetic and dyslipidemic; and 3 diabetic, hypertensive, and smokers). The final 14% (33 patients) represents the population enrolled for our study. The control group consisted of healthy volunteers enrolled between the staff members of both the Departments of Cardiology and Dermatology.
Echocardiographic Measurements
Two-dimensional echocardiographic images were acquired using ultrasound equipment (MyLab Alpha, Esaote, Florence, Italy) with a 2.5-MHz phased array transducer. The 2D data measurements were obtained, according to the recommendations of the American Society for Echocardiography, by parasternal long and short axes and by 3 standard apical windows. An analysis of wall motion, end-diastolic volume, end-systolic volume, and ejection fraction (EF) was carried out as well as the measurement of peak A, E and E 0 waves, E deceleration time (Dt), and isovolumetric relaxation time (IVRT). Diastolic function was assessed by the ratio of early and late diastolic mitral inflow velocities (E/A ratio), the Dt, the IVRT, and by the E/E 0 ratio.
Speckle Tracking Analysis by 2D Echocardiography
A dedicated software package (XStrain; Esaote) was used for an "off-line" quantification of circumferential ( Figure 1A ) and longitudinal strain ( Figure 1B ). The LV was divided according to the 16-segment model (6 basal, 6 mid-level, and 4 apical). Short-axis scans were obtained at the mitral valve, papillary muscles, and apical levels and used to assess CS. Longitudinal strain (LS) was calculated using standard apical 4-, 3-, and 2-chamber scans. Global strain was defined as the mean value of all the 16 segments. In all patients, the global CS (GCS) and the global LS (GLS) were calculated.
Evaluation of PWV
Carotid-femoral PWV was measured using pulsed wave Doppler analysis synchronized with electrocardiogram with a linear probe. We performed 3 recordings from the common carotid artery and 3 from the femoral artery at the groin region. Each recording involved at least 3 cardiac cycles. Transit time (TT) was estimated by the time from the R wave of QRS to the foot of the waveforms at each site. In order to determine PWV, the ratio between the distance measured from the sternal notch to the femoral artery at the groin and TT was calculated, according to the following formula: PWV ¼ distance/(T2 À T1).
Data Analysis
Data were assessed for equality of variance and distribution. Descriptive statistics with means and median, as appropriate, and proportions were used to describe continuous and categorical variables. Unpaired t tests were used to test differences in demographic and clinical characteristics and to test cardiac and echocardiographic parameter differences between cases and controls. The association between categorical variables was evaluated using the w 2 test. Correlation analyses were performed by means of the nonparametric Spearman rank correlation test. All statistical tests were 2 sided, and a P < .05 was considered significant. Statistical tests were conducted using the statistical software package SigmaPlot (version 11.0; Systat Software, Inc., San Jose, California) and SAS (version 9.0; SAS Institute Inc, Cary, North Carolina).
Results
Demographic and Clinical Characteristics
We studied a total of 33 patients with psoriasis and 33 normal controls from February 2015 to May 2016. The characteristics of the cases and controls are listed in Table 1 . The mean psoriasis duration was 5.6 + 1.7 years, and the disease severity was PASI 7.3 + 1.8. Patients and controls were well matched with regard to demographic characteristics. The mean age did not differ significantly between the patients with psoriasis and controls. Just over half were males. Body mass index did not differ significantly between the patients with psoriasis and control participants. In addition, there were no significant differences in systolic blood pressure, diastolic blood pressure, and heart rate. None of the participants in either group had other conditions that are known to or could reasonably be expected to affect cardiac function, echocardiographic characteristics, and arterial stiffness. Specifically, no participant in either group was affected by any conventional CV risk factor (eg, arterial hypertension, diabetes mellitus, dyslipidemia, smoke, or chronic kidney disease).
Echocardiographic Characteristics
Comparisons of the echocardiographic conventional indexes between patients with psoriasis and controls are summarized in Table 2 . No significant differences were observed in LV end-diastolic diameter, interventricular septum, and posterior wall thickness. There were no significant differences in LV end-diastolic volume, LV end-systolic volume, and EF. Furthermore, early diastolic mitral inflow velocity (E), late diastolic mitral inflow (A), the E/A ratio, Dt, and IVRT did not differ significantly between the patients and the controls. Speckle tracking analysis showed that GLS values were significantly lower (P ¼ .002) in patients with psoriasis (22.39% + 2.28%) than in controls (24.15% + 2.17%; Figure 2A ); for GCS, there were no significant differences (P ¼ .16; Figure 2B) .
A correlation between the GLS and disease duration (r ¼ À.66, P < .0001; Figure 3A ) and a correlation between the GLS and the patient age at which the diagnosis was made (r ¼ .48, P ¼ .0043; Figure 3B ) were also observed. No other correlations were found. In particular, no correlations between GLS and PASI, age, or gender were observed.
Pulse Wave Velocity Characteristics
Analysis of the PWV characteristics showed values of arterial stiffness significantly lower (P ¼ .004) in controls (8.06 + 1.68 m/s) than in patients with psoriasis (9.23 + 1.53 m/s; Figure 2C ).
Discussion
Our main findings are:
1. Global longitudinal strain was significantly lower in patients with psoriasis than in controls. 2. Global circumferential strain was not significantly different between the 2 groups. 3. There was a significant correlation between GLS and disease duration. 4. There was a significant correlation between GLS and patient age at first diagnosis. 5. Arterial stiffness values were significantly higher in patients with psoriasis compared to controls.
These results were obtained in patients with untreated mild psoriasis and without any other condition affecting cardiac function, echocardiographic characteristics, and arterial stiffness. Specifically, none of the participants in both groups was affected by conventional CV risk factors.
There is evidence that links the presence of psoriasis, in association with other CV risk factors, with an increased prevalence of myocardial ischemia, cerebrovascular disease, and peripheral artery disease. [28] [29] [30] [31] [32] Other studies concluded that psoriasis leads to a worse prognosis in patients with previous myocardial infarction. 33 However, another study did not confirm an increase in incidence and/or prevalence of myocardial infarction in patients with psoriasis, although it was not possible to exclude a modest increase in CV risk. 34 Because of this evidence, psoriasis, alone or in combination with other CV risk factors, could play a role in the development and progression of myocardial ischemia, but its exact contribution is not completely clear, especially when considered as a "stand-alone" risk factor.
Our results suggest that psoriasis, in the absence of other CV risk factors, is associated with subclinical alterations in both cardiac function and arterial stiffness.
Guven et al reported comparable LV dimensions, wall thickness, and EF between patients with psoriasis and healthy controls. 35 Similarly, Ardic et al showed no differences in LV diameters or EF. 36 Also, the results of our study show that all conventional echocardiographic parameters are comparable between patients with mild psoriasis and controls.
Cardiac function abnormalities were observed by 2D-SE, a technique that can detect minimal abnormalities in systolic and regional LV function. 17, [37] [38] [39] In our patients, the GLS values were significantly lower compared to controls, suggesting subclinical reductions in longitudinal function. Furthermore, a recent study demonstrated (using 2D strain imaging) that patients with psoriasis have lower LV function. 40 In the same study, there were also significant differences in some parameters of diastolic function. These differences were not present in our study probably because their patients were older than ours (41.1 + 3.8 years) with a greater PASI score (15.8 + 7.7).
We did not find significant differences in terms of GCS. Interpretation of these results can be very challenging, but we think that LV anatomy, function, and perfusion play a role. Longitudinal function is mainly driven by deformation of the subendocardial fibers, which are the most vulnerable and most sensitive to perfusion changes. [14] [15] In this subclinical stage of LV systolic dysfunction, mesocardium and epicardium fibers could be involved in a compensation mechanism, resulting in normal circumferential mechanics and pump function and, therefore, in normal GCS and EF. [14] [15] [16] [17] In this study, we found that LV dysfunction correlated with the duration of the disease. A possible explanation is that patients with longer disease duration could have developed more inflammatory damage than those ones with a shorter duration. Furthermore, the novelty that emerges from our results is that cardiac functional impairment was more severe in younger patients, irrespective of duration and severity. These data agree with those of Sunbul et al. 41 However, the main difference with their study is that they included patients with various degrees of psoriasis (PASI 13.7 + 8.9), treated with topical and/or systemic drugs (including retinoids, photochemotherapy, methotrexate, cyclosporine, etanercept, or infliximab), while our patients had mild psoriasis (PASI < 10) and were not treated for psoriasis nor for other diseases. Our results suggest that psoriasis is independently associated with an arterial stiffness, which is significantly higher in affected patients than in controls.
The chronic systemic inflammation related to psoriasis could be involved in the damage of the vascular endothelium and in its function, leading to greater arterial stiffness. This hypothesis is consistent with other studies. [42] [43] [44] There are several important clinical implications deriving from our work. We studied a relatively young patient group (mean age 35.6 years) with mild psoriasis, without any evidence of CVD, other concomitant conditions, and without any pharmacological treatment.
We demonstrated that assessment of cardiac performance parameters, by 2D-SE, and assessment of arterial stiffness parameters, by PWV, may be used as markers for screening CV risk. In this context, dermatologists should pay attention to CV risk when managing patients with mild psoriasis, allowing them to benefit from early intervention.
Our study has several limitations. First, there is no follow-up in order to evaluate the incidence of major CV events related to the risk deriving from psoriasis. Inflammation biomarkers were not sampled even if we hypothesized a central role for chronic inflammation 45 in the worsening of cardiac performance and of vascular stiffness in mild psoriasis. However, this was only an assumption made retrospectively, the main aim being to measure any functional cardiac and/or vascular modification in the absence of other confounding factors (comorbidities and/or therapies). This objective was reached demonstrating that these patients have significant reduction in GLS and significant rise in PWV compared to healthy controls.
Psoriasis, in its mild form, may be an independent CV risk factor associated with impairment of cardiac performance and increased vascular stiffness even in the absence of other risk factors. Impairment of cardiac function is greater with longer disease duration and as patient age is lower. Both 2D-SE and PWV may be used as tools for screening CV risk.
Further studies are required to fully understand the underlying mechanisms of CV dysfunction to evaluate the incidence of major CV events and to identify proper strategies for slowing down CV damage progression in these patients.
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